Pacific Biosciences of California Balance Sheet Health
Financial Health criteria checks 3/6
Pacific Biosciences of California has a total shareholder equity of $701.3M and total debt of $892.7M, which brings its debt-to-equity ratio to 127.3%. Its total assets and total liabilities are $1.7B and $1.0B respectively.
Key information
127.3%
Debt to equity ratio
US$892.73m
Debt
| Interest coverage ratio | n/a |
| Cash | US$634.42m |
| Equity | US$701.30m |
| Total liabilities | US$1.04b |
| Total assets | US$1.75b |
Recent financial health updates
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?
Jul 11Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?
Feb 24Recent updates
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?
Jul 31Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Jul 06Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Mar 29Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?
Feb 26Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook
Aug 08Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio
Jul 27Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?
Jul 11Pacific Biosciences Hit By Sentiment, But The Future Of Long-Read Sequencing Is Strong
Apr 05Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?
Feb 24Financial Position Analysis
Short Term Liabilities: PACB's short term assets ($742.0M) exceed its short term liabilities ($95.0M).
Long Term Liabilities: PACB's short term assets ($742.0M) do not cover its long term liabilities ($949.7M).
Debt to Equity History and Analysis
Debt Level: PACB's net debt to equity ratio (36.8%) is considered satisfactory.
Reducing Debt: PACB's debt to equity ratio has increased from 12.9% to 127.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PACB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PACB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.